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ABSTRACT 
Objective: The objective of the current study was to demonstrate the three year outcome of 
the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) technique for 
the treatment of extensive aortoiliac occlusive disease (AIOD). 
Methods: Between February 2009 and July 2016, all patients treated with the CERAB 
technique for AIOD were identified in the local databases of two centers and analyzed. 
Demographics and lesion characteristics were scored. Follow-up (FU) consisted of clinical 
assessment, duplex ultrasound and ankle brachial indices (ABI). Patency rates and clinically 
driven target lesion revascularization (CD-TLR) were calculated by Kaplan-Meier analysis. 
Results: 130 patients (69 male and 61 female) were treated of which 68% patients were 
diagnosed with intermittent claudication and 32% suffered from critical limb ischemia. The 
vast majority (89%) were TASC-II D lesions and the remaining were TASC-II B and C (both 
5%). Median follow-up was 24 months (range 0-67 months). The technical success rate was 
97% and 67% of cases were performed completely percutaneously. The ABI improved 
significantly from 0.65 ± 0.22 preoperatively to 0.88 ± 0.15 after the procedure. The 30-day 
minor and major complication rate was 33% and 7%. The median hospital stay was 2 days 
(range 1-76 days ). At 1 and 3-years FU 94% and 96% of the patients clinically improved at 
least 1 Rutherford category (2% and 0% unchanged, 4% and 4% worsened). Limb salvage 
rate at 1-year was 98% and 97% at three year follow-up. Primary, primary-assisted and 
secondary patency was 86%/91%/97% at 1-year, 84%/89%/97% at 2-year and 82%/87%/97% 
at 3-year FU. Freedom from CD-TLR was 87% at 1-year and 86% at both 2 and 3-year FU. 
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Conclusions: The CERAB technique is a safe and feasible technique for the treatment of 
extensive aortoiliac occlusive disease with good three year results regarding patency and 
clinical improvement.  
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INTRODUCTION 
The last decades have shown a clear trend towards endovascular interventions as the first-line 
treatment strategy for aortoiliac occlusive disease (AIOD), also as a solution for complex 
lesions. Endovascular treatment of AIOD has been related to less morbidity and a shorter 
hospital stay, compared to open surgery 1. In addition, open reconstruction is related to late 
complications, including incisional hernia formation. The kissing stent (KS) technique, using 
two stents abutting or ‘kissing’ in the central lumen of the distal aorta, is most commonly used 
when the aortic bifurcation is involved. A recent review showed that the primary patency of 
KS at 2-year follow-up is 79%, with 48% TASC C or D lesions treated 2. The geometry of the 
KS configuration was previously identified as a risk factor for re-stenosis and thrombosis 3-5. 
The cross configuration in KS influences the mismatch areas between the stent and vessel 
wall that, in turn, causes flow disturbances. This is thought to be the main cause of impaired 
patency, related to neointimal hyperplasia induced by low oscillating wall shear stress and 
stagnant blood flow 6. To overcome these disadvantages and to achieve better long-term 
patency, our groups introduced a new technique in 2013 named the covered endovascular 
reconstruction of the aortic bifurcation (CERAB) technique 7. We previously showed that this 
configuration is related to a superior flow geometry and more physiological flow patterns, in 
vitro 8, 9. In 2015 the early results of the CERAB technique were published with 1-year 
primary and secondary patency rates of 87% and 95%, respectively. These were considered to 
be promising, particularly since they included all treated patients from two sites including the 
first-in-man 10. In the present study we have evaluated three year outcomes of the same cohort 
and updated it with the more recently treated patients. 
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METHODS 
Patients 
All patients treated with the CERAB technique between February 2009 and July 2016 in two 
hospitals, the Rijnstate Hospital Arnhem (Netherlands) and the ZNA Vascular Clinic 
(Belgium) were identified and analyzed retrospectively. Human investigation review board 
approval was obtained for this study and patient informed consent was not required, related to 
the retrospective design. Patients treated for acute limb ischemia and/or with chimney 
configurations were excluded from the analysis 11. Prior to endovascular treatment all patients 
were treated with anti-platelet therapy, statins and (supervised) walking exercise. Medical 
files were screened for demographic data, clinical status, using the Rutherford classification 
for chronic ischemia 12, complications and information on follow-up. Lesions were 
categorized according to the TASC–II criteria by assessing the Computed Tomographic 
Angiography (CT-A) scans 13, 14. Procedural reports were used to extract information on the 
procedure and the stent types used. The pre-treatment runoff resistance score for the iliac 
outflow was calculated based on the runoff grading scheme as proposed by Rutherford et al 12. 
A three point degree of stenosis scale was used to gauge the resistance, < 50% stenosis = 0, > 
50% stenosis = 1 and occlusion = 2, based on duplex ultrasound. Weighting units are divided 
among the relative contribution to runoff; 2 for the external iliac artery (EIA) and 1 for the 
internal iliac artery (IIA). The maximal combined runoff score for left and right was 12 (left+ 
right = (2*2+2*1)+(2*2+2*1)). Follow-up was scheduled after 6 weeks, 6, 12, 24, 36, 48 and 
60 months and consisted of clinical assessment and duplex ultrasound with ankle-brachial 
indices (ABI) measurements. Due to the low number of patients with a completed FU of 48 
and 60 months FU up till 36 months is reported in the Results section.  
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CERAB procedure 
Suitability for the technique was evaluated based on CT-A imaging. Details on the CERAB 
technique have been described before 7. Briefly, two introducer sheaths are placed in the 
common femoral arteries. The lesion is crossed either endoluminally or subintimally, 
depending on the lesion characteristics (Fig 1A, verifying re-entrance). After pre-dilatation, a 
9 Fr introducer sheath is inserted above the proximal margin of the aortic lesion. Thereafter, a 
12-mm balloon expandable ePTFE covered stent (Atrium Advanta V12, Maquet Getinge, 
Hudson, NH, USA) is deployed in the distal aorta. The distal end of the stent is placed 
approximately 15 to 20 millimeters above the bifurcation to facilitate canalization. This stent 
is flared proximally with a balloon adapted to the native diameter of the distal aorta, typically 
with a diameter of 16 mm, to ensure full apposition to the aortic wall. This creates a funnel-
shaped stent with a distal segment that is still 12 mm in diameter. Subsequently, two iliac 
covered stents, typically 8 mm, are positioned in the conic segment and simultaneously 
inflated (Fig. 1B). As treatment planning is always from healthy-to-healthy tissue, in some 
cases distal extensions are required (Fig. 1B). In these cases we try to preserve the internal 
iliac arteries, if patent, using a bare metal stent at these locations to prevent buttock 
claudication and erectile dysfunction. Post procedure, patients receive statin treatment and 
dual antiplatelet therapy for at least six months after which single antiplatelet and statin 
therapy is continued. 
Definitions 
Primary outcome of the study was the 3-year primary patency. Secondary outcome measures 
included assisted-primary patency, secondary patency, freedom from clinical driven target 
lesion revascularization (CD-TLR), technical success, clinical improvement, length of 
hospital stay, 30 day morbidity, mortality and secondary interventions. Patency was 
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determined by means of duplex ultrasound (PSV<2.5). Primary patency was defined as 
patency that is obtained without the need for additional or secondary surgical or endovascular 
procedures 15. Assisted-primary patency is defined as patency of the configuration achieved 
with the use of an additional or secondary surgical or endovascular procedure, as long as 
occlusion of the treated segment has not occurred 15. Secondary patency was defined as the 
patency achieved by all procedures to recanalize an occluded CERAB configuration, 
preserving the configuration. Freedom from CD-TLR was defined as the time between the 
procedure and any revascularization based on restenosis and or occlusion and return or 
increase of symptoms. Technical success was achieved when blood flow was restored with 
less than 30% residual stenosis. Restenosis was defined as a PSV ratio > 2.5, measured 
proximal, in or distal to the graft on duplex ultrasound. Major and minor complications were 
registered up until 30 days after the procedure. Complications leading to transient impairment 
were scored as minor. Complications leading to permanent damage or death were scored as 
major 15. Limb salvage rate was defined as all patients without above the ankle amputations. 
Statistics 
Data are presented as mean ± standard variation, unless stated otherwise. The Shapiro-Wilk 
test was used to test for normality. Statistical analysis was performed using SPSS 24 (IBM 
Corp. in Armonk, NY, USA). The non-parametric Chi-square test was used to test for 
differences in outcome with respect to previous vascular interventions, learning curve, 
intermittent claudication (IC) vs. critical limb ischemia (CLI) and impaired runoff. The paired 
student T-test was used to compare ABI pre- and postoperative. An ANOVA for repeated 
measures was used to test the difference in Rutherford category pre- and postoperative. 
Univariate analysis was used to identify any correlation between smoking, diabetes, 
hypertension, renal status, cardiac status and pulmonary status and patency. Kaplan-Meier 
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survival analysis was used to calculate patency numbers. The Log-rank test was used to 
compare the resulting survival curves. Statistical significance was defined as P < .05.  
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RESULTS 
During the study period a total of 130 patients (69 male and 61 female) were treated with the 
CERAB technique at the two sites. Patient characteristics are depicted in Table I and Figure 2. 
One patient was classified as Rutherford category 1, as he was preventively treated for an 
aortobifemoral prosthesis at risk for occlusion because of high grade stenosis at the proximal 
anastomosis. The majority of lesions (n=116, 89%) were classified as TASC-II D, the 
remaining were TASC-II B and C (both n=7, 5%). Seven patients had previously undergone a 
surgical reconstruction of the aortoiliac segment: five aorto-bi-iliac bypasses, one ileo-femoral 
and one femoro-femoral crossover bypass. Another 46 patients (35%) had previously 
undergone an endovascular intervention; 46% of these interventions were angioplasties of the 
common iliac artery (in 17% kissing balloon) and 37% were angioplasties with stenting of the 
common iliac artery (31% KS), Table I provides details on the remaining interventions. Prior 
to the intervention 35% (n=44) had no stenosis in one of the outflow vessels, 35% (n=44) had 
a stenosis and 30% (n=38) had an occlusion in one of the outflow vessels (either left or right). 
Further details per vessel segment are presented in Table I. Median follow-up was 23.5 
months (range 0-67 months). Follow-up at 24 and 36 months was available in 56 and 37 
cases, respectively. 
Procedural results  
The technical success rate was 97%. In 4 cases technical success was not obtained; in three 
patients no re-entry could be obtained and in one the lesion could not be passed. All technical 
failures occurred within the first 40 treated patients (case 20, 24, 37 and 39). Most procedures 
were performed by bilateral percutaneous access of the common femoral arteries (n=87, 
67%). In 15% of cases (n=20) a surgical cut down of both femoral arteries was performed, 
combined with an endarterectomy of the common femoral artery in 65% of them (n=13). In 
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18% of the procedures (n=23) a percutaneous access technique was used on one side and 
surgical cut down was performed on the contralateral side. At the location of the cut down this 
was combined with an endarterectomy in 52% of the procedures. Brachial access was used in 
two procedures. 
Three covered stents were used in 55% (n=67) of the cases, 4 in 19% (n=23), 5 in 22% (n=27) 
and more than 6 stents in 4% (n=5). The aortic stent was predominantly used in the 
dimensions 12x41 mm (n=77) or 12x61 mm (n=34). Limbs (left + right) were deployed with a 
diameter x length of 8x59 mm (n=190), 8x38 mm (n=30) and 6x59 mm (n=10). In a number 
of cases the limb was extended into the external iliac artery to reach healthy tissue (14% to the 
right and 15% to the left side). The mean procedure time was 152.7 ± 88 minutes and mean 
amount of contrast used was 122.5 ± 62.4 mL. Median hospital stay was 2 days (range 1 to 76 
days); 54% of the patients stayed in hospital for 1-2 days; 29% of the patients stayed 3-5 days 
and 6% were admitted for longer than 5 days. 
In 11% of the cases there were procedural complications, including unintentional dissection, 
arterial rupture or thrombosis (Table II) and all of them were solved during the initial 
procedure. In one patient an extensive bleeding in the left common iliac artery led to a 
resuscitation after cardiac arrest and subsequent prolonged ICU and hospital stay (76 days). 
The patient died, with an unknown cause of death, 3 months after discharge. 
Clinical outcome 
Postoperative complications are depicted in Table II. Minor complications occurred in 43 
cases (33%), in 33 cases (77%) these were hematoma, ecchymosis or leg edema. A re-
intervention was necessary in 2 cases with a minor complication, both requiring thrombin 
injection for a false aneurysm at the access site. In 8% of the treated patients major 
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postoperative complications occurred: stent collapse in one of the limbs in three cases; in one 
case the CERAB was explanted and replaced with an aorto-bi-femoral graft and in two cases a 
kissing balloon technique was used to restore the flow lumen of the collapsed limb (Fig. 3). 
Another patient was re-operated for an occlusion of the femoral artery attributed to a 
misplaced closure device. In two cases an early thrombosis of the CERAB occurred, both 3 
weeks postoperatively. Both were successfully treated; one by thrombectomy and the other by 
thrombolysis. Postoperative deterioration of chronic renal insufficiency occurred in one 
patient without the need for dialysis. This patient, treated for Rutherford category 5, died 4 
months postoperative. The 30-day mortality rate was 0%.  
Clinical improvement, expressed as an increase of at least one Rutherford category, at 6 
weeks follow-up was 87%. No improvement was observed in 11% of the patients and in 3% it 
worsened (max. 1 category). The median Rutherford category changed from 3 (min: 1, max: 
6) preoperative to a median of 0 (min: 0, max: 5) postoperative (P<.05). At 24 and 36 months 
the median Rutherford category was 0 (min: 0, max: 6) and 0 (min: 0, max: 6), both 
significantly different with respect to the preoperative staging, an overview is given in Figure 
2. The ABI significantly improved from 0.65 ± 0.22 preoperatively to 0.88 ±0.15 after the 
procedure (P<.05). At 24 and 36 months the ABI was 0.97 ±0.14 and 0.99 ±0.14.  
In total 3% of patients underwent toe amputations, three within 30 days and one during the 
procedure (unrelated to the procedure). The preoperative Rutherford classification was 5 in 
two cases and 6 in two cases. After 3-year follow-up 4 (3%) major amputations (under or 
above the knee) were performed, at 6 months (n=1), 12 months (n=1) and 24 months (n=2) 
FU, respectively. The initial Rutherford classification was 4 in three cases and 5 in one case. 
Limb salvage rate at 1-year was 98% and 97% at three year follow-up. The overall survival at 
12 
 
1 and 3-year FU was 93% and 88%, respectively. In total 12 patients died during the 3-year 
follow-up. 
Patency 
The patency rates are depicted in Figure 4. The primary patency was 86% after 12 months, 
84% after 24 months and 82% after 36 months. Univariate analyses showed no significant 
relation between primary patency and smoking, diabetes, hypertension, renal insufficiency or 
coronary disease. No differences in outcome were observed between the first 20 treated in 
each clinic and the patients treated thereafter (P=.54 and P=.28), and as such a clear learning 
curve effect could not be established. 
Outcome between patients with and without a history of previous vascular interventions 
(either surgical or endovascular) was not significantly different (P=.26). More details are 
presented in Table III. There was no significant difference (P=.24) in primary patency for 
patients with an increased runoff score (score 1-12) prior to treatment and patients without 
(score 0). Furthermore, grouped initial Rutherford indication (IC vs. CLI) did not influence 
the primary patency results (P=.61). 
Reinterventions 
During the follow-up period CERAB-related reinterventions were performed in 18 patients 
(14%) (Table IV). 72% of the patients received one or two reinterventions and the majority of 
them were performed within the first 12 months after the initial procedure (88%). Apart from 
reinterventions other (endo)vascular interventions were performed in 27 patients (21%). In 
67% of the cases this was either a plain balloon angioplasty (PBA) or PBA and stenting of the 
outflow arteries.  
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DISCUSSION 
In the present study we have demonstrated that patency and clinical outcome of the CERAB 
technique for extensive AIOD is satisfying, with three-year primary, primary-assisted and 
secondary patency rates of 82%, 87% and 97%, respectively. The technical success rate was 
100% in the last 90 procedures, and in many of them open surgery would have been the only 
alternative treatment modality. Technically, there are no anatomical or morphological lesion 
boundaries for indication of the CERAB technique. The amount of (circular) calcification is 
not considered to be an exclusion criterion for the technique. In cases presenting lesions just 
distal to the renal arteries the chimney CERAB technique of the inferior mesenteric artery was 
applied (not included in the present study)11. However, the overall health situation of the 
patient has to be taken into account and in relatively fit patients open surgical repair may be 
preferred over the use of chimney’s in the visceral arteries. 
Eighty-eight percent of reinterventions were performed within the first year after treatment, 
which is reflected in the stable patency rates afterwards. These results stand firm amidst 
results that are obtained with the KS technique, with 2-year primary patency of 79% (range 
58-92%) and also compared to aorto-bi-femoral grafts, with a 2-year primary patency of 93% 
(range 87-98%) 2, 16, 17. It should be noted, however, that more complex lesions were treated in 
the current study, when compared to most results reported for KS and open repair, both 50% 
TASC-C&D lesions, making the comparison less reliable 2, 16. Only the cohort of Dorigo and 
colleagues had a comparable distribution of the TASC categories 17.  
Flow and geometry seem to be important factors in view of stent patency. In previously 
published papers we studied the influence of the KS and CERAB technique on radial 
mismatch and blood flow using in vitro modeling 8, 9. The effects of different stent 
configurations on flow perturbations were investigated and these studies showed that the 
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CERAB configuration is the most unimpaired physiologic reconstruction with only a few 
zones of recirculation and little fluid stasis. Lowering flow disturbances and radial mismatch, 
i.e. mimicking a native bifurcation, could lower thrombus formation and thereby restenosis 18. 
The 30-day major complication rate of 8% is low in comparison to the 30-day major 
complication rate of 20% reported after aorto-bi-femoral and aorto-bi-iliac bypass procedures 
19 and in line with respect to those observed after KS treatment (5.8% ± 4.4%, TASC C&D in 
50% of cases) 2. Therefore, the results of this study show that the technique is indeed a 
valuable alternative for these treatment options. 
The relation between patency and outflow has previously been shown for KS by several 
studies 4, 16 while it was not observed by others 20, 21. Therefore, the impact of impaired runoff 
in aortoiliac stenting remains under debate. Studies that did observe the aforementioned 
relation pointed out that the atherosclerotic process might be more virulent in patients with 
extensive PAD and impaired runoff. This underlines the importance of proper risk 
management using statins, antiplatelet drugs and walking exercise. However, the optimal 
duration of double antiplatelet therapy has never been studied in this respect, and should be 
the topic of further research. 
First signs of patency loss are usually observed on duplex ultrasound. According to the study 
of Chong et al. peak systolic velocity (PSV) values above average are commonly reported 
during duplex follow-up in the CERAB configuration, and could require a CT-A for further 
assessment 22. CT-A data often reports a patent configuration, therefore Chong and colleagues 
proposed a tool to predict the maximal peak systolic velocity (PSV) in the CERAB. In future 
studies it would be interesting to incorporate such tools and to evaluate their predictive value. 
Most reinterventions were performed within the first 12 months after treatment. This 
emphasizes that strict follow-up in the first 12 months is paramount to detect onset of re-
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stenosis, while follow-up afterwards could be less frequent. With this FU schedule a 
secondary patency rate of 97% can be achieved at three-year follow-up.  
In the present study, patency was defined according to the reporting standards, as recently 
described by Stoner et al. 15. In other studies, including our first paper on the outcome after 
CERAB, another definition was used, that includes the presence of a significant stenosis as 
loss of primary patency 10. In the current cohort there were only two cases with such a 
stenosis left untreated, and as such the influence on the results is only minimal with a 3-year 
primary patency of 81% vs. 82%. Standardization of definitions and adherence to reporting 
standards is key and requires attention when comparing data from different studies. 
In the current cohort four technical failures were reported and in all cases the lesion could not 
be passed from a retrograde direction. Brachial access was not attempted in these cases. 
Nowadays, brachial access is applied in our centers in challenging cases and is a viable option 
in case of a failed retrograde approach 23. When comparing the major complication rate with 
the complications observed in our early series, a 4-fold increase was noted (2% vs 8%). This 
could be related to the fact that over time more complex lesions were considered to be 
suitable for the technique and also underlines frailty of this group of patients. Three of the 
complications were caused by a crushed iliac stent in the aortic cuff (two examples shown in 
Fig. 3). In one of them this was likely to be a technical error where the aortic cuff was post-
dilated after positioning of the limbs, thereby crushing the contralateral limb. In the other two 
cases no clear reason was observed, however, could have been related to the heavily calcified 
lesions. Improvement of stent design and additional knowledge on stent mechanics may also 
contribute to the prevention of this complication. In addition, a relining stent could be used to 
add radial force to the CERAB configuration. However, relining the CERAB configuration as 
a preventive measure would significantly increase cost. Furthermore, to our knowledge no 
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lesion morphology or geometry characteristics can predict stent crushing. When diagnosing 
stent collapse, PBA in combination with relining could be beneficial, since the original 
configuration might be weakened. 
The choice of stents was based on studies that reported a superior patency of covered stents 
over bare metal stents in treatment of TASC C and D lesions 24-27. In 45% of the cases we 
could not complete the procedure with three stents only, emphasizing the need for longer 8 
mm diameter limbs (currently limited to 58 mm length). In the current cohort the CERAB was 
mostly constructed using Advanta Atrium V12 stents. Due to manufacturing problems since 
2015 the large diameter Atrium Maquet V12 stents are no longer available. In search of 
alternatives the LifeStream (BARD Peripheral Vascular, Tempe, AZ, USA) and more recently 
the Begraft and Begraft Aortic (Bentley Innomed GmbH, Hechingen, Germany) were used for 
this indication. Future research should point out what the differences are between these three 
balloon-expandable stents with respect to placement accuracy, radial force, durability of the 
ePTFE layer and patency. Parallel to the introduction of the CERAB the use of the AFX 
unibody bifurcation endograft (Endologix Inc, Irvine, Calif, USA) was described for 
treatment of AIOD 28, 29. The benefit of this stent is the fact that radial mismatch is completely 
prevented, but being a self-expanding stent the AFX stent has less radial force. 
The present study is limited by the fact that it describes the first experience of a novel 
technique. With gaining experience results were likely to improve, but broadening indication 
for the technique during time may also have affected results. Furthermore, the retrospective 
analyses of our registry limited us to draw firm conclusions on causation of failure of patency. 
Moreover, the 3-year follow-up was not completed for the entire cohort, and as such only 
reflects early experience. Nevertheless, the standard error of the patency rate estimate was 
below 10%. 
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Conclusion 
This study has shown that the CERAB technique is related to good three year results, with 
regard to patency and clinical outcome, in patients treated for mostly TASC-II D lesions. 
Long-term studies should establish its role in these patients and risk-prediction tools need to 
be assessed.   
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